Abstract 1721: Deletion of Both Macrophage ABCG1 and ApoE Independently Promotes Atherosclerotic Lesion Development in LDL Receptor Knockout Mice

Circulation ◽  
2008 ◽  
Vol 118 (suppl_18) ◽  
Author(s):  
Ruud Out ◽  
Bart Lammers ◽  
Reeni B. Hildebrand ◽  
Carmel M. Quinn ◽  
David Williamson ◽  
...  

Objective ATP-binding cassette transporter G1 (ABCG1) and apolipoprotein E (apoE) play a role in macrophage cholesterol efflux and consequently the development of atherosclerosis. Although a possible interaction between ABCG1 and apoE in cholesterol efflux was postulated, the combined action of these proteins in atherosclerosis is still unclear. Methods and Results LDL receptor knockout (KO) mice were transplanted with bone marrow from ABCG1/apoE double KO (dKO) mice, their respective single knockouts, and wild-type (WT) controls. After feeding a high-fat/high-cholesterol diet for 6 weeks, no differences were found in serum lipid levels. However, the mean atherosclerotic lesion area in dKO transplanted animals (187 ± 18 × 10 3 μ m 2 ) was 1.4-fold (p < 0.01) increased compared to single knockouts (ABCG1 KO: 138 ± 5 × 10 3 μm 2 ; apoE KO: 131 ± 7 × 10 3 μm 2 ) and 1.9-fold (p< 0.001) as compared to WT controls (97 ± 15 × 10 3 μm 2 ). In vitro cholesterol efflux experiments confirmed that combined deletion of ABCG1 and apoE resulted in a larger attenuation of macrophage cholesterol efflux to HDL as compared to single knockouts. Conclusions Deletion of macrophage ABCG1 or apoE does lead to a moderate increase in atherosclerotic lesion development while combined deletion of ABCG1 and apoE induces a more dramatic increase in atherosclerosis. These results indicate an added, independent effect for both macrophage ABCG1 and apoE in atherosclerosis.

Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
Illiana Meurs ◽  
Ruud Out ◽  
Menno Hoekstra ◽  
Reeni B Hildebrand ◽  
Theo J Van Berkel ◽  
...  

ATP-binding cassette transporter G1 (ABCG1) facilitates the efflux of cholesterol from macrophages to HDL. As ABCG1 plays a role in preventing cellular lipid accumulation, macrophage ABCG1 expression has been suggested to protect against atherosclerosis. In bone marrow transplantation studies, however, we and others obtained different effects of specific macrophage ABCG1-deficiency on atherosclerotic lesion development under different experimental settings. The objective of this study was to further define the effect of ABCG1-deficiency on lipid metabolism and atherosclerotic lesion development. ABCG1 knockout (KO) mice upon atherogenic diet feeding develop only modest atherosclerotic lesions, therefore, we recently cross-bred ABCG1 KO mice with LDL-receptor KO (LDLr KO) mice. LDLr KO and LDLr/ABCG1 double KO (dKO) littermates were fed a high-fat, high-cholesterol Western-type diet (WTD) containing 0.25% cholesterol and 15% fat for 10 weeks to induce atherosclerotic lesion formation. Both on chow diet and on WTD, serum lipid levels and lipoprotein profiles showed no significant differences between the LDLr KO and LDLr/ABCG1 dKO mice. However, after 10 weeks of diet feeding, a significant 1.5-fold increase in atherosclerotic lesion size was observed in the aortic root of LDLr/ABCG1 dKO mice (130 ± 12x10 3 μm 2 [n = 8] compared to 88 ± 11x10 3 μm 2 [n=7] for LDLr KO mice; p =0.026). In addition, macrophage-rich areas of the lungs and spleens of LDLr/ABCG1 dKO mice exhibited excessive lipid accumulation compared with LDLr KO mice. Furthermore, in vitro studies using bone marrow derived macrophages of LDLr KO and LDLr/ABCG1 dKO mice showed that disruption of ABCG1 results in a 15% decrease in cholesterol efflux to HDL ( p< 0.001), whereas the cholesterol efflux to ApoAI was unaffected. These studies reveal that total-body ABCG1 deficiency leads to increased atherosclerotic lesion development and massive lipid accumulation in macrophages of the lung and spleen, possibly due to impaired efflux of cholesterol from macrophages deficient in ABCG1. In conclusion, the expression of ABCG1 protects against atherosclerotic lesion development.


Circulation ◽  
2015 ◽  
Vol 132 (suppl_3) ◽  
Author(s):  
Joshua P Samsoondar ◽  
Brian G Sutherland ◽  
Dawn E Telford ◽  
Cynthia G Sawyez ◽  
Jane Y Edwards ◽  
...  

ETC-1002 (8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid) is a novel LDL cholesterol-lowering compound. Preclinical studies revealed that ETC-1002 targets the liver where its metabolite, ETC-1002-CoA, inhibits the synthesis of sterols and fatty acids. The primary mechanism of action is through inhibition of hepatic ATP-citrate lyase (ACL). In the current study we tested the ability of ETC-1002 to prevent diet-induced metabolic dysregulation, inflammation and atherosclerosis in LDL receptor deficient (Ldlr-/-) mice. Ldlr-/- mice fed a high-fat high-cholesterol diet (42% kcal fat; 0.2% cholesterol; HFHC) developed hypercholesterolemia, hypertriglyceridemia, hyperglycemia, hyperinsulinemia, fatty liver and obesity over the 12 week study. ETC-1002 supplementation to the HFHC diet at 3, 10 and 30 mg/kg/d significantly attenuated these metabolic abnormalities in a dose-dependent manner. ETC-1002 + HFHC attenuated plasma triglyceride (up to 64%) and plasma cholesterol concentrations (up to 50%), and improved glucose homeostasis compared to HFHC alone as determined by glucose tolerance tests. Adiposity was attenuated up to 48% with treatment. In liver, ETC-1002 dose dependently prevented cholesterol and triglyceride accumulation up to 75% and 90%, respectively. Hepatic gene expression analysis revealed that treatment significantly reduced the expression of the inflammatory genes Tnfa, Il1b, Ccl3 and Nos2 as well as increased the expression of genes involved in mitochondrial (Cpt1a, 1.3-fold) and peroxisomal (Acox1, 4.1-fold) fatty acid beta-oxidation. ETC-1002 reduced aortic cholesterol ester content by up to 63% and robustly attenuated atherosclerotic lesion development in the aortic sinus by 48%. These studies demonstrate that ETC-1002 effectively prevents plasma and tissue lipid elevations and attenuates the onset of inflammation, leading to the prevention of atherosclerotic lesion development in a mouse model of metabolic dysregulation.


PLoS ONE ◽  
2013 ◽  
Vol 8 (5) ◽  
pp. e63360 ◽  
Author(s):  
Martine Bot ◽  
Paul P. Van Veldhoven ◽  
Saskia C. A. de Jager ◽  
Jason Johnson ◽  
Niels Nijstad ◽  
...  

2002 ◽  
Vol 70 (9) ◽  
pp. 5332-5334 ◽  
Author(s):  
Erwin Blessing ◽  
Lee Ann Campbell ◽  
Michael E. Rosenfeld ◽  
Cho-chou Kuo

ABSTRACT Chlamydia pneumoniae has been shown to accelerate atherosclerotic lesion development in hyperlipidemic animals. This study showed that C. pneumoniae did not accelerate lesion development in mice if a high-fat/high-cholesterol diet was started after infection, indicating that C. pneumoniae is a co-risk factor with hyperlipidemia for cardiovascular disease.


Vaccine ◽  
2011 ◽  
Vol 29 (5) ◽  
pp. 976-983 ◽  
Author(s):  
Thomas van Es ◽  
Gijs H.M. van Puijvelde ◽  
Ingrid N. Michon ◽  
Eva J.A. van Wanrooij ◽  
Paula de Vos ◽  
...  

2005 ◽  
Vol 135 (4) ◽  
pp. 729-734 ◽  
Author(s):  
Byambaa Enkhmaa ◽  
Kuninori Shiwaku ◽  
Takuya Katsube ◽  
Keiko Kitajima ◽  
Erdembileg Anuurad ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document